Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor.

Journal article

In a murine relapsing experimental allergic encephalomyelitis (EAE) model, gene therapy to block TNF was investigated with the use of a retroviral dimeric p75 TNF receptor (dTNFR) construct. To effectively produce these TNF inhibitors in vivo, a conditionally immortalized syngeneic fibroblast line was established, using a temperature-sensitive SV40 large T Ag-expressing retrovirus. These cells were subsequently infected with a retrovirus expressing soluble dTNFR. CNS-injected cells could be d...

Expand abstract

Authors: Croxford, J; Triantaphyllopoulos, K; Neve, R; Feldmann, M; Chernajovsky, Y

• Publication status: Published
• Journal: Journal of Immunology
• Volume: 164
• Issue: 5
• Pages: 2776-2781
• Publication date: 2000-03-01
• DOI: 10.4049/jimmunol.164.5.2776
• EISSN: 1550-6606
• ISSN: 0022-1767
• Language: English
• Keywords: Humans; Chronic Disease; Fibroblasts; Animals; Acute Disease; Gene Therapy; Brain Tissue Transplantation; Cell Line, Transformed; Dimerization; Solubility; Encephalomyelitis, Autoimmune, Experimental; Antigens, CD; Kidney; Receptors, Tumor Necrosis Factor, Type II; Recurrence; Receptors, Tumor Necrosis Factor; Genetic Vectors; Mice; Injections, Intraventricular